U.S. markets open in 2 hours 24 minutes
  • S&P Futures

    4,460.50
    -13.75 (-0.31%)
     
  • Dow Futures

    34,665.00
    -84.00 (-0.24%)
     
  • Nasdaq Futures

    15,485.50
    -32.25 (-0.21%)
     
  • Russell 2000 Futures

    2,218.50
    -9.40 (-0.42%)
     
  • Crude Oil

    72.19
    -0.42 (-0.58%)
     
  • Gold

    1,762.80
    +6.10 (+0.35%)
     
  • Silver

    23.02
    +0.23 (+0.99%)
     
  • EUR/USD

    1.1783
    +0.0011 (+0.09%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    19.41
    +1.23 (+6.77%)
     
  • GBP/USD

    1.3794
    -0.0003 (-0.02%)
     
  • USD/JPY

    109.9830
    +0.2650 (+0.24%)
     
  • BTC-USD

    47,478.59
    -408.54 (-0.85%)
     
  • CMC Crypto 200

    1,205.99
    -27.30 (-2.21%)
     
  • FTSE 100

    7,011.64
    -15.84 (-0.23%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

StemCells completes enrollment in spinal cord injury trial

StemCells announced that it has completed enrollment in the Company's Phase I/II clinical trial in spinal cord injury. The multi-national, open-label, Phase I/II trial is evaluating both safety and preliminary efficacy of StemCells, Inc.'s proprietary HuCNS-SC human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve subjects with chest-level injury to the spinal cord. The trial enrolled seven patients with complete paralysis, no motor or sensory function below the point of injury, classified as complete, according to the American Spinal Injury Association Impairment Scale, and five patients with no motor function and limited sensory function below the point of injury classified as incomplete. Final results from this landmark study are expected to be released mid-2015.